Conduit Pharmaceuticals (CDT) News Today $0.55 -0.01 (-2.00%) As of 02:11 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Conduit Pharmaceuticals files to sell 2.1M shares of common stock for holdersApril 22, 2025 | msn.comConduit Pharmaceuticals announces Regan appointed as CEOApril 17, 2025 | markets.businessinsider.comConduit Pharmaceuticals Announces Leadership ChangesApril 16, 2025 | globenewswire.comConduit Pharmaceuticals announces novel cocrystal patent filing for VTAMAApril 11, 2025 | markets.businessinsider.comConduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension ProspectsApril 11, 2025 | globenewswire.comConduit expands parntership with SarborgApril 8, 2025 | markets.businessinsider.comConduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline OptimizationApril 7, 2025 | markets.businessinsider.comConduit Pharmaceuticals receives U.S. patent approval for AZD1656April 2, 2025 | markets.businessinsider.comConduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune DiseasesMarch 31, 2025 | globenewswire.comConduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline DevelopmentMarch 21, 2025 | nasdaq.comConduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656March 21, 2025 | nasdaq.comConduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904March 20, 2025 | markets.businessinsider.comConduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904March 19, 2025 | globenewswire.comConduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price RegainingMarch 8, 2025 | nasdaq.comIs Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comConduit granted extension by Nasdaq to regain complianceMarch 6, 2025 | markets.businessinsider.comConduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing PanelMarch 6, 2025 | globenewswire.comConduit Pharmaceuticals progresses Phase II of AI initiative with SarborgFebruary 20, 2025 | markets.businessinsider.comConduit Progresses Phase II of its AI Initiative with SarborgFebruary 20, 2025 | globenewswire.comConduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus ModelFebruary 13, 2025 | globenewswire.comConduit announces debt repayment, conversion of senior secured noteFebruary 11, 2025 | markets.businessinsider.comConduit Pharmaceuticals settles debt, converts senior noteFebruary 11, 2025 | msn.comConduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured NoteFebruary 11, 2025 | globenewswire.comConduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase IIFebruary 8, 2025 | insidermonkey.comConduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug DevelopmentFebruary 7, 2025 | markets.businessinsider.comConduit Pharmaceuticals transitions to Phase II of Sarborg collanFebruary 7, 2025 | markets.businessinsider.comConduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug DevelopmentFebruary 7, 2025 | globenewswire.comConduit Pharmaceuticals files to sell 5.9M shares of common stock for holdersFebruary 6, 2025 | markets.businessinsider.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Sees Significant Decrease in Short InterestConduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,750,000 shares, a drop of 67.6% from the December 31st total of 11,570,000 shares. Based on an average daily volume of 52,100,000 shares, the short-interest ratio is currently 0.1 days.January 28, 2025 | marketbeat.comConduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial IntelligenceJanuary 28, 2025 | globenewswire.comConduit Pharmaceuticals board approves 1-for-100 reverse stock splitJanuary 24, 2025 | markets.businessinsider.comMurphy Canyon stock hits 52-week low at $0.05 amid steep declineJanuary 23, 2025 | msn.comConduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standardsJanuary 23, 2025 | msn.comConduit Pharmaceuticals Approves 1-for-100 Reverse Stock Split, Stock FallsJanuary 23, 2025 | markets.businessinsider.comConduit Pharmaceuticals Inc. Announces Reverse Stock SplitJanuary 23, 2025 | globenewswire.comConduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune PipelineJanuary 23, 2025 | markets.businessinsider.comConduit Pharmaceuticals faces Nasdaq delisting over price, votes for reverse splitDecember 23, 2024 | investing.comConduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock SplitDecember 21, 2024 | markets.businessinsider.comConduit and Sarborg link to optimise AI drug developmentDecember 14, 2024 | msn.comConduit Pharmaceuticals to enter agreement with SARBORDecember 13, 2024 | markets.businessinsider.comConduit Collaborates With Sarborg To Facilitate Drug Development, Stock Up In Pre-MarketDecember 12, 2024 | markets.businessinsider.comConduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and CyberneticsDecember 12, 2024 | globenewswire.comConduit Pharmaceuticals receives further patent approval for AZD1656November 21, 2024 | markets.businessinsider.comWhat's Going On With Conduit Pharmaceuticals Shares Today?November 21, 2024 | benzinga.comConduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune DisordersNovember 21, 2024 | globenewswire.comConduit Pharmaceuticals Announces Leadership Changes and Bylaws UpdateNovember 20, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces Appointment of Simon Fry to Board of DirectorsNovember 19, 2024 | globenewswire.comConduit Pharmaceuticals announces new addition to autoimmune pipelineNovember 5, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces New Addition to its Autoimmune PipelineNovember 4, 2024 | globenewswire.comConduit Pharmaceuticals Secures Funding and Modifies Debt AgreementsNovember 1, 2024 | markets.businessinsider.com Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address CDT Media Mentions By Week CDT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDT News Sentiment▼0.440.85▲Average Medical News Sentiment CDT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDT Articles This Week▼21▲CDT Articles Average Week Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MIRA Pharmaceuticals News GlycoMimetics News ABVC BioPharma News NeuroSense Therapeutics News Cocrystal Pharma News Phio Pharmaceuticals News IN8bio News Cellectar Biosciences News 23andMe News Moleculin Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDT) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDT Stock Free CDT Stock Alerts